AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8629630 — intervention group
Group type: EXPERIMENTAL
Intervention: mupirocin calcium ointment 2% applied daily to the exit site
Number of subjects: 82
Study 8629630 — intervention group
Group type: COMPARATOR
Intervention: cyclic oral rifampin 600 mg for 5 days every 3 months
Number of subjects: 82
Study 1592640 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-nail
Number of subjects: 100
Study 1592640 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 100
Study 6691784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (N = 14)
Number of subjects: 28
Study 6691784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (N = 14)
Number of subjects: 28
Study 6691784 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy and Pharmacotherapy (N = 28)
Number of subjects: 28
Study 31064968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy during chemotherapy
Number of subjects: 50
Study 31064968 — intervention group
Group type: COMPARATOR
Intervention: Usual care (0.9% normal saline gargles three times before meals)
Number of subjects: 50
Study 31064968 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy
Number of subjects: 50
Study 31064968 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 28620848 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 28620848 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SoC) platinum-based chemotherapy
Number of subjects: 0
Study 27137715 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (8, 15, 30, 60, 125, 250, 500, and 1000mg)
Number of subjects: 46
Study 27137715 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (250 and 1000mg)
Number of subjects: 46
Study 27137715 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxegol (up to 1000mg)
Number of subjects: 46
Study 27137715 — intervention group
Group type: COMPARATOR
Intervention: Naloxegol
Number of subjects: 46
Study 27137715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 23798725 — intervention group
Group type: COMPARATOR
Intervention: telcagepant 600 mg
Number of subjects: 24
Study 23798725 — intervention group
Group type: COMPARATOR
Intervention: sumatriptan 100 mg
Number of subjects: 24
Study 23798725 — intervention group
Group type: COMPARATOR
Intervention: telcagepant 600 mg with sumatriptan 100 mg
Number of subjects: 24
Study 22041444 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid paraffin sections (group A)
Number of subjects: 176
Study 22041444 — intervention group
Group type: COMPARATOR
Intervention: Conventional paraffin sections (group B)
Number of subjects: 176
Study 19208459 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 15microg BID
Number of subjects: 234
Study 19208459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18microg QD
Number of subjects: 234
Study 19208459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (arformoterol 15microg BID and tiotropium 18microg QD)
Number of subjects: 234
Study 19208459 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 234
Study 16445833 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Self-Management (PSM)
Number of subjects: 104
Study 16445833 — intervention group
Group type: COMPARATOR
Intervention: Patient Self-Testing (PST)
Number of subjects: 104
Study 16445833 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 104
Study 16445833 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual patients
Number of subjects: 104
Study 16214453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 11054
Study 11131273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg daily for 8 weeks
Number of subjects: 17
Study 11131273 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine 5-10 mg daily for 8 weeks
Number of subjects: 17
Study 11131273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 5-10 mg daily for 8 weeks followed by Lisinopril 10-20 mg daily for another 8 weeks
Number of subjects: 17
Study 9078198 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1202
Study 9078198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1202
Study 1606777 — intervention group
Group type: COMPARATOR
Intervention: rHuEpo 40 U/kg intravenously three times weekly (Group 1)
Number of subjects: 12
Study 1606777 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEpo 40 U/kg intravenously three times weekly with nandrolone decanoate 2 mg/kg weekly (Group 2)
Number of subjects: 12
Study 1606777 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 1)
Number of subjects: 12
Study 1606777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (Group 2)
Number of subjects: 12
Study 3982646 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Number of subjects: 10
Study 3982646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2832549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 20 mg/m2 X 4 plus etoposide (VP‐16) 100 mg/m2 X 4 every 4 weeks for two courses
Number of subjects: 160
Study 2832549 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (control)
Number of subjects: 160
Study 2832549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus VP‐16
Number of subjects: 160
Study 31813045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 20
Study 31813045 — intervention group
Group type: COMPARATOR
Intervention: SHAM
Number of subjects: 20
Study 29606711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health first aid training (MHFA)
Number of subjects: 163
Study 29606711 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal depression (PND) roleplay
Number of subjects: 163
Study 29606711 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide roleplay
Number of subjects: 163
Study 29606711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both roleplays (PND and suicide)
Number of subjects: 163
Study 28597226 — intervention group
Group type: EXPERIMENTAL
Intervention: AL 441 mg q4wk
Number of subjects: 140
Study 28597226 — intervention group
Group type: EXPERIMENTAL
Intervention: AL 882 mg q6wk
Number of subjects: 140
Study 28597226 — intervention group
Group type: EXPERIMENTAL
Intervention: AL 1064 mg q8wk
Number of subjects: 140
Study 25428945 — intervention group
Group type: EXPERIMENTAL
Intervention: Speckle tracking echocardiography (STE) in CKD patients
Number of subjects: 106
Study 23952901 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory presentation of a story through headphones
Number of subjects: 110
Study 23952901 — intervention group
Group type: COMPARATOR
Intervention: Routine care with no auditory recording (Control)
Number of subjects: 110
Study 21145034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin during first and second stages of labor
Number of subjects: 11323
Study 21145034 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of third stage of labor (AMTSL)
Number of subjects: 11323
Study 18498885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 20
Study 18498885 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide (CH)
Number of subjects: 20
Study 17023435 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with 1000 cGy beta radiation
Number of subjects: 450
Study 17023435 — intervention group
Group type: COMPARATOR
Intervention: Standard trabeculectomy without beta radiation (placebo)
Number of subjects: 450
Study 12687595 — intervention group
Group type: COMPARATOR
Intervention: Systemic dexamethasone and aerosol placebo (Control)
Number of subjects: 61
Study 12687595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aerosol beclomethasone (2.40-3.69 microg/kg/day)
Number of subjects: 61
Study 12687595 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose aerosol beclomethasone (1.0-1.85 microg/kg/day)
Number of subjects: 61
Study 12687595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aerosol beclomethasone (0.48-0.74 microg/kg/day)
Number of subjects: 61
Study 12687595 — intervention group
Group type: COMPARATOR
Intervention: Systemic dexamethasone (Control)
Number of subjects: 61
Study 11085838 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video about colon cancer screening
Number of subjects: 249
Study 11085838 — intervention group
Group type: COMPARATOR
Intervention: Generic brochure on automobile safety (Control)
Number of subjects: 249
Study 8642081 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% glycolic, lactic, or citric acid lotion
Number of subjects: 0
Study 8642081 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 0
Study 1471614 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjinyoeito
Number of subjects: 3
Study 6363490 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation technique (deep abdominal breathing, tensing and relaxing body parts, relaxation by autosuggestion, voluntary image control)
Number of subjects: 22
Study 6363490 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation technique
Number of subjects: 22
Study 31750484 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple rice
Number of subjects: 22
Study 31750484 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunlu29 (red) rice
Number of subjects: 22
Study 31750484 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiziq (brown) rice
Number of subjects: 22
Study 28337945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy integrated with motivational interviewing (MI-CBT)
Number of subjects: 85
Study 28337945 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy alone (CBT)
Number of subjects: 85
Study 27080115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/Paracetamol
Number of subjects: 170
Study 27080115 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac K/Paracetamol
Number of subjects: 170
Study 27080115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic Acid/Paracetamol
Number of subjects: 170
Study 27080115 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol alone
Number of subjects: 170
Study 27080115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 24535029 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal (CSW)
Number of subjects: 872
Study 24535029 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid continuation (CSC)
Number of subjects: 872
Study 22775123 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious participants
Number of subjects: 40
Study 22775123 — intervention group
Group type: COMPARATOR
Intervention: Nonanxious participants
Number of subjects: 40
Study 20434544 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose regimen of combined hepatitis A and B vaccine (0, 6 months, Adult formulation)
Number of subjects: 0
Study 20434544 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dose regimen of combined hepatitis A and B vaccine (0, 1, 6 months, Paediatric formulation)
Number of subjects: 0
Study 20434544 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge dose of hepatitis B vaccine administered to subjects with anti-HBs antibody concentration < or =10mIU/mL
Number of subjects: 0
Study 18300356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with lamivudine-IFN-alpha 2b for 48 weeks
Number of subjects: 71
Study 18300356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy for 48 weeks
Number of subjects: 71
Study 18300356 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2b monotherapy for 24 weeks
Number of subjects: 71
Study 18300356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HBeAg seroconversion
Number of subjects: 71
Study 18300356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with sustained virological response after 24 weeks of therapy withdrawal
Number of subjects: 71
Study 18300356 — intervention group
Group type: COMPARATOR
Intervention: HBV genotype C
Number of subjects: 71
Study 16231260 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fluconazole (200 mg 3 times weekly)
Number of subjects: 829
Study 16231260 — intervention group
Group type: COMPARATOR
Intervention: Episodic fluconazole (provided only for episodes of OPC or EC)
Number of subjects: 829
Study 16231260 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fluconazole
Number of subjects: 829
Study 16231260 — intervention group
Group type: COMPARATOR
Intervention: Episodic fluconazole
Number of subjects: 829
Study 11249886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive strategy (maximum burr/artery >0.70 with adjunctive balloon inflation < or = 1 atm)
Number of subjects: 497
Study 11249886 — intervention group
Group type: COMPARATOR
Intervention: Routine strategy (maximum burr/artery < or = 0.70 with routine balloon inflation > or = 4 atm)
Number of subjects: 497
Study 11249886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 497
Study 9593717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara h1 protein with amino acid substitutions in IgE binding epitopes
Number of subjects: 0
Study 9593717 — intervention group
Group type: EXPERIMENTAL
Intervention: Ara h1 protein
Number of subjects: 0
Study 7988775 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in the insulin gene region in Caucasians
Number of subjects: 840
Study 7988775 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in the insulin gene region in Tanzanian blacks
Number of subjects: 840
Study 7988775 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in the insulin gene region in Japanese orientals
Number of subjects: 840
Study 7988775 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-associated genotype INS +/+
Number of subjects: 840
Study 7988775 — intervention group
Group type: COMPARATOR
Intervention: Contribution of particular HLA-DQ alleles
Number of subjects: 840
Study 2925776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 40
Study 2925776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 31624941 — intervention group
Group type: COMPARATOR
Intervention: Same-day dose (SDD) of polyethylene glycol (PEG) starting at 7 AM on the day of colonoscopy
Number of subjects: 193
Study 31624941 — intervention group
Group type: EXPERIMENTAL
Intervention: Split dose (SPD) of polyethylene glycol (PEG) - 2 L at 9 PM the day before and 2 L from 10 AM on the day of colonoscopy
Number of subjects: 193
Study 31624941 — intervention group
Group type: COMPARATOR
Intervention: Same-day dose (SDD)
Number of subjects: 193
Study 31624941 — intervention group
Group type: EXPERIMENTAL
Intervention: Split dose (SPD)
Number of subjects: 193
Study 30281073 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Incentive for Pre-schools project training intervention (manager-only or manager and staff)
Number of subjects: 37
Study 28102979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 30
Study 28102979 — intervention group
Group type: COMPARATOR
Intervention: Present‐centered therapy
Number of subjects: 30
Study 26457716 — intervention group
Group type: EXPERIMENTAL
Intervention: Very severely obese women
Number of subjects: 241
Study 26457716 — intervention group
Group type: COMPARATOR
Intervention: Lean women
Number of subjects: 241
Study 23111018 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting plus surgical ventricular reconstruction
Number of subjects: 555
Study 23111018 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 555
Study 23111018 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 555
Study 22091798 — intervention group
Group type: EXPERIMENTAL
Intervention: LightSheer Duet HS
Number of subjects: 36
Study 22091798 — intervention group
Group type: COMPARATOR
Intervention: LightSheer ET
Number of subjects: 36
Study 19459427 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg/day) with indapamide (1.5 mg/day)
Number of subjects: 46
Study 17553395 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric home visits (n=59)
Number of subjects: 102
Study 17553395 — intervention group
Group type: COMPARATOR
Intervention: Subacute admittance to geriatric ward (n=43)
Number of subjects: 102
Study 14716538 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic cholecystectomy (RLC)
Number of subjects: 20
Study 14716538 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 20
Study 11473038 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide (40-80 mg twice daily for 5 weeks)
Number of subjects: 10
Study 11473038 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide (acute treatment)
Number of subjects: 10
Study 11473038 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide (5 weeks treatment)
Number of subjects: 10
Study 11473038 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 10
Study 9742715 — intervention group
Group type: EXPERIMENTAL
Intervention: Escape option provided to participants (monkeys and humans) during memory tasks
Number of subjects: 0
Study 9742715 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-detection analyses
Number of subjects: 0
Study 9742715 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimality analyses
Number of subjects: 0
Study 8066559 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (800 micrograms beclomethasone daily)
Number of subjects: 155
Study 8066559 — intervention group
Group type: COMPARATOR
Intervention: Bronchodilators only (control group)
Number of subjects: 155
Study 2929469 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training for 4 months
Number of subjects: 26
Study 29946644 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM all‐ceramic inlays
Number of subjects: 97
Study 29946644 — intervention group
Group type: COMPARATOR
Intervention: Ceramage polymerid porcelain inlay
Number of subjects: 97
Study 28804807 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) injection
Number of subjects: 31
Study 28804807 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo) injection
Number of subjects: 31
Study 25744003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level transcutaneous electrical vagus nerve stimulation (LLTS) for 1 hour (20 Hz)
Number of subjects: 40
Study 25744003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level transcutaneous electrical vagus nerve stimulation (LLTS)
Number of subjects: 40
Study 25744003 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 40
Study 23682827 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cell network profiling (SCNP) classifier
Number of subjects: 121
Study 21283543 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 20
Study 21283543 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without Atorvastatin
Number of subjects: 20
Study 19255328 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA 5-2-2 (75 mg/m(2)/d for 5 days, then 2 days no treatment, then 75 mg/m(2)/d for 2 days)
Number of subjects: 151
Study 19255328 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA 5-2-5 (50 mg/m(2)/d for 5 days, then 2 days no treatment, then 50 mg/m(2)/d for 5 days)
Number of subjects: 151
Study 19255328 — intervention group
Group type: EXPERIMENTAL
Intervention: AZA 5 (75 mg/m(2)/d for 5 days)
Number of subjects: 151
Study 16109807 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (AT1 receptor blocker)
Number of subjects: 14
Study 16109807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15120009 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhaled from Easyhaler (Giona Easyhaler)
Number of subjects: 229
Study 15120009 — intervention group
Group type: COMPARATOR
Intervention: Budesonide inhaled from Turbuhaler (Pulmicort Turbuhaler)
Number of subjects: 229
Study 15120009 — intervention group
Group type: COMPARATOR
Intervention: Budesonide inhaled from Turbuhaler
Number of subjects: 229
Study 15120009 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhaled from Easyhaler
Number of subjects: 229
Study 11227931 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric transrectal stimulation of the pudendal nerve
Number of subjects: 19
Study 11227931 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the sacral roots
Number of subjects: 19
Study 8651164 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of a dual antimony pH electrode catheter across the LES
Number of subjects: 23
Study 8651164 — intervention group
Group type: COMPARATOR
Intervention: Catheter placement 5 cm and 20 cm above the LES
Number of subjects: 23
Study 2180405 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral methotrexate (MTX)
Number of subjects: 281
Study 2180405 — intervention group
Group type: COMPARATOR
Intervention: Daily auranofin (AUR)
Number of subjects: 281
Study 395523 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg daily for 2 months)
Number of subjects: 27
Study 395523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30239629 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Improving Self-Management Strategy (AIMS)
Number of subjects: 223
Study 30239629 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 223
Study 28158978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-incision release
Number of subjects: 67
Study 28158978 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic release
Number of subjects: 67
Study 28158978 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 67
Study 25865966 — intervention group
Group type: EXPERIMENTAL
Intervention: Blond orange juice (200 mL, 3 times daily for 4 weeks)
Number of subjects: 25
Study 25865966 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (200 mL, 3 times daily for 4 weeks)
Number of subjects: 25